Médecine

Paramédical

Autres domaines


S'abonner

The risk of urinary tract infections in patients with psoriasis on systemic medications in Biobadaderm Registry: A prospective cohort study - 11/02/20

Doi : 10.1016/j.jaad.2019.07.028 
Antonio Sahuquillo-Torralba, MD a, , Gregorio Carretero, MD, PhD b, Raquel Rivera, MD c, Carlos Ferrándiz, MD, PhD d, Esteban Daudén-Tello, MD, PhD e, Pablo de la Cueva, MD, PhD f, Francisco José Gómez-García, MD g, Isabel Belinchón, MD, PhD h, Enrique Herrera-Acosta, MD i, Diana Ruiz-Genao, MD j, Marta Ferrán, MD k, Mercé Alsina, MD, PhD l, Jose Luís Sánchez-Carazo, MD, PhD m, Ofelia Baniandrés, MD, PhD n, Lourdes Rodríguez Fernández-Freire, MD o, Jaime Vilar, MD b, Carmen García-Donoso, MD c, Jose Manuel Carrascosa, MD, PhD d, Mar Llamas-Velasco, MD, PhD e, Enrique Herrera-Ceballos, MD, PhD i, José Luis López-Estebaranz, MD j, Conrad Pujol-Marco, MD p, Miguel Ángel Descalzo, MSc, PhD q, Ignacio García-Doval, MD, PhD q, r
the

Biobadaderm Study Group

a Department of Dermatology, Hospital Universitario y Politécnico La Fe, Instituto de Investigación Sanitaria La Fe, Valencia, Spain 
b Department of Dermatology, Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de Gran Canaria, Spain 
c Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain 
d Department of Dermatology, Hospital Universitari Germans Trias i Pujol, Badalona, Universidad Autónoma de Barcelona, Barcelona, Spain 
e Department of Dermatology, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria La Princesa, Madrid, Spain 
f Department of Dermatology, Hospital Universitario Infanta Leonor, Madrid, Spain 
g Department of Dermatology, Hospital Universitario Reina Sofía, Cordoba, Spain 
h Department of Dermatology, Hospital General Universitario de Alicante, Alicante, Spain 
i Department of Dermatology, Hospital Universitario Virgen de la Victoria, Málaga, Spain 
j Department of Dermatology, Fundación Hospital de Alcorcón, Madrid, Spain 
k Department of Dermatology, Hospital del Mar-Parc de Salut Mar, Barcelona, Spain 
l Department of Dermatology, University Hospital Clínic de Barcelona, Barcelona, Spain 
m Department of Dermatology, Hospital General Universitario de Valencia, Valencia, Spain 
n Department of Dermatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain 
o Department of Dermatology, Hospital Virgen del Rocío, Sevilla, Spain 
p Department of Dermatology, Hospital Universitario y Politécnico La Fe, Valencia, Spain 
q Research Unit, Fundación Piel Sana AEDV, Madrid, Spain 
r Department of Dermatology, Complexo Hospitalario Universitario de Vigo, Vigo, Spain 

Correspondence to: Antonio Sahuquillo-Torralba, MD, Fundación Piel Sana AEDV, Calle Ferraz 100, Madrid, SpainFundación Piel Sana AEDVCalle Ferraz 100MadridSpain

 Funding sources: The Biobadaderm project is promoted by the Fundación Piel Sana Academia Española de Dermatología y Venereología, which receives financial support from the Spanish Medicines and Health Products Agency (ie, Agencia Española de Medicamentos y Productos Sanitarios) and from the pharmaceutical companies Abbott/AbbVie, Pfizer, MSD, Novartis, Lilly, Janssen, and Almirall.
 Conflicts of interest: Dr Sahuquillo-Torralba has served as a consultant or paid speaker for or participated in clinical trials sponsored by companies that manufacture drugs used for the treatment of psoriasis, including AbbVie, Celgene, Janssen-Cilag, LEO Pharma, Lilly, Novartis, and Pfizer. Dr Carretero has been reimbursed by Janssen, AbbVie, Novartis, Pfizer, MSD, and Celgene for advisory service and conference. Dr Rivera acted as consultant or speaker for or participated in clinical trials as a principle investigator for AbbVie, Almirall, Celgene, Janssen, LEO Pharma, Lilly, Novartis, MSD, and Pfizer-Wyeth. Dr Ferrándiz has served as a consultant or paid speaker for or participated in clinical trials sponsored by companies that manufacture drugs used for the treatment of psoriasis, including AbbVie, Amgen, Celgene, Janssen-Cilag, LEO Pharma, Lilly, Merck Sharp & Dohme, Novartis Pfizer, and Almirall.
 Dr Daudén-Tello acted as consultant for Abbott, Amgen, Astellas, Centocor Ortho Biotech Inc, Galderma, Glaxo, Janssen-Cilag, LEO Pharma, Novartis, Pfizer, MSD, and Celgene; received honoraria form Abbott, Amgen, Janssen-Cilag, LEO Pharma, Novartis, Pfizer, MSD, Celgene; participated in a speakers bureau for Abbott, Pfizer, MSD, and Janssen; and received grants from Pfizer, Abbott, Janssen, and MSD. Dr de la Cueva acted as a consultant or speaker for Janssen-Cilag, AbbVie, MSD, Pfizer, Novartis, Lilly, Almirall, UCB, Biogen, Celgene, Amgen, Sandoz, Sanofi, and LEO Pharma. Dr Belinchón acted as a speaker or advisor for Janssen Pharmaceuticals Inc, Almirall SA, Lilly, AbbVie, Novartis, Celgene, Biogen Amgen, LEO Pharma, Pfizer-Wyeth, and MSD. Dr Herrera-Acosta has served as consultant or speaker for LEO Pharma, Novartis, Janssen, Lilly, Celgene, and AbbVie. Dr Ferran has participated as speaker or advisor for Janssen, Lilly, Novartis, Pfizer, MSD, AbbVie, Celgene, and Almirall. Dr Ruiz-Genao has been reimbursed by Pfizer, Janssen, Celgene, AbbVie, Novartis, and LEO Pharma for advisory services and conferences. Dr Alsina gave expert testimony for Merck-Schering Plough, Pfizer, Janssen, Novartis, LEO Pharma, Almirall, and Abbott. Dr Baniandrés acted as a consultant or speaker for Janssen-Cilag, AbbVie, Pfizer, Novartis, Lilly, and Almirall. Dr Rodriguez Fernandez-Freire acted as a consultant and speaker for Janssen-Cilag, AbbVie, MSD, Pfizer, Novartis, Lilly, Almirall, Celgene, and LEO Pharma. Dr Carrascosa has participated as a speaker or advisor for Celgene, Janssen, Lilly, Novartis, LEO Pharma, Pfizer, MSD, AbbVie, Biogen, and Amgen. Dr Llamas-Velasco acted as a consultant and speaker for Janssen-Cilag, AbbVie, Celgene, Pfizer, Novartis, Lilly, Almirall, and LEO Pharma and has participated in clinical assays. Dr Herrera-Ceballos has served as a consultant or speaker for or principal investigator of clinical trials sponsored by companies that manufacture drugs used for the treatment of psoriasis, including AbbVie, Janssen-Cilag, LEO Pharma, Lilly, Novartis, and Pfizer.
 Dr López-Estebaranz participated as a consultant and received educational grants from Janssen, AbbVie, MSD, Lilly, Novartis, LEO Pharma, and Pfizer. Dr García-Doval received travel grants for congresses from AbbVie, MSD, and Pfizer.
 Dr Gómez-García, Dr Sánchez-Carazo, Dr Vilar, Dr Pujal-Marco, and Dr Descalzo have no conflicts of interest to disclose.
 Disclaimer: Collaborating pharmaceutical companies were not involved in the design and conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.
 IRB status: Observational study. Approved (Biobadaderm: Hospital Universitario 12 de Octubre (216/07).
 Reprints not available from the authors.


© 2019  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 82 - N° 3

P. 738-741 - mars 2020 Retour au numéro
Article précédent Article précédent
  • Increased risk of second primary malignancies in patients with mycosis fungoides: A single-center cohort study
  • Amrita Goyal, Daniel O'Leary, Kavita Goyal, Nathan Rubin, Kimberly Bohjanen, Maria Hordinsky, Steven T. Chen, Lyn M. Duncan, Georgios Pongas, Aleksandr Lazaryan
| Article suivant Article suivant
  • Peripheral cutaneous head and neck melanoma: Definition, characteristics, and impact on survival
  • José Antonio Avilés-Izquierdo, Enrique Rodríguez-Lomba, Jakob Milla, Ignacio Hernández-Aragüés

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.